Electroencephalography

EMOTIV Enlists Two Machine Learning Heavyweights as AI Takes Aim at the Human Brain

Retrieved on: 
Monday, May 1, 2023
Psychology, Learning, Natural language processing, Digital Writing and Research Lab, Clipboard, Data science, Electroencephalography, Intelligence, Wall Street, Overture, Brain, Research, Data mining, Medicine, Publication, Yahoo!, Machine learning, SAN, EEG, Engineering, Artificial intelligence, Knowledge, Robotics, Health, Microsoft Live Labs, Salesforce, Medical device, Management, Mobile phone, Citadel

Dr. Flake has been appointed CTO for EMOTIV after helming R&D teams for large technology companies across two decades.

Key Points: 
  • Dr. Flake has been appointed CTO for EMOTIV after helming R&D teams for large technology companies across two decades.
  • Dr. Flake has filed over 150 patents and has authored numerous publications focused on machine learning, data mining, and complex systems.
  • We are approaching the inflection point when silicon-based technology can actually decode the human brain, unlock its mysteries, even correct its disorders.
  • There’s never been a more immense opportunity to use data science to improve human health – and the human experience.”

Interaxon Inc. (Muse®) Announces Jean-Michel Fournier as New CEO

Retrieved on: 
Thursday, April 13, 2023
Mental Health, Wearables, Mobile Technology, Technology, Medical Devices, Neurology, Other Technology, Nanotechnology, Software, Health, Data Management, Electroencephalography, BDC, Partner (business rank), Mindfulness, NYSE, EEG, Corporation, Bodi, Growth, Relaxation, Hewlett-Packard, Mental health, UnitedHealth Group, Phillip Mills, Management, Muses

Fournier brings a wealth of experience in scaling high-growth companies and driving innovation in the health and wellness space.

Key Points: 
  • Fournier brings a wealth of experience in scaling high-growth companies and driving innovation in the health and wellness space.
  • Fournier joins Interaxon from BODi (NYSE:BODY), the leading digital wellness and nutrition subscription company, where he served as President of Corporate Development & Strategic Partnerships.
  • Prior to this, Fournier was the co-founder & CEO of the mobile and computer vision platform BitGym, and held several senior executive roles at UnitedHealth Group and Hewlett Packard.
  • “We are thrilled to welcome Jean-Michel to Interaxon,” said Lally Rementilla, Interaxon board chair and Managing Partner, IP-Backed Financing, BDC Capital.

Brain Mapping Instruments Market to Reach $3.7 Billion, Globally, by 2031 at 6.1% CAGR: Allied Market Research

Retrieved on: 
Friday, March 31, 2023
Seizure, Maintenance, Magnetic resonance, Prevalence, Alzheimer's disease, Table, Neoplasm, Hospital, Stroke, COVID-19, NIRS, PET, CT scan, DSM-IV codes, PEM, Chart, MRI, Toxic injury, Hydrocephalus, Page, Investment, Patient, Myenteric plexus, EEG, Brain mapping, Growth, PDF, Magnetic resonance imaging, Positron emission tomography, Medical imaging, Electroencephalography

PORTLAND, Ore., March 31, 2023 /PRNewswire/ -- Allied Market Research published a report, titled, "Brain Mapping Instruments Market by Product Type (Computed Tomography, Positron Emission Tomography (PET), Electroencephalography (EEG), Near-Infrared Spectroscopy (NIRS), Magnetic Resonance Imaging (MRI), Others), by End User (Hospitals, Ambulatory Centers, Others): Global Opportunity Analysis and Industry Forecast, 2021-2031." According to the report, the global brain mapping instruments industry generated $2.1 billion in 2021 and is anticipated to generate $3.7 billion by 2031, witnessing a CAGR of 6.1% from 2022 to 2031.

Key Points: 
  • According to the report, the global brain mapping instruments industry generated $2.1 billion in 2021 and is anticipated to generate $3.7 billion by 2031, witnessing a CAGR of 6.1% from 2022 to 2031.
  • The market for brain mapping instruments is experiencing growth due to various factors such as an increase in the prevalence of brain-related conditions like Alzheimer's disease, epilepsy seizures, toxic injuries, and tumors.
  • Additionally, there is a rise in the number of neurological incidents among populations, a growing geriatric population, and increased awareness and adoption of advanced brain mapping technologies.
  • Based on region, the market in North America accounted for more than two-fifths of the global brain mapping instruments market and is likely to dominate in terms of revenue during the forecast period.

Trevena Reports Fourth Quarter 2022 Results and Provides Business Update

Retrieved on: 
Thursday, March 30, 2023
Epilepsy, Vomiting, Male, Cleveland Clinic, Central nervous system, Senior, Delirium, ARTEMIS, Atrium Health Wake Forest Baptist, EMR, Trevena, PACU, Confusion Assessment Method, CNS, Richmond Agitation-Sedation Scale, Sale, Incidence, Data analysis, Length of stay, Patient, Central nervous system disease, Risk, Nausea, Webcast, Transcranial magnetic stimulation, Hospital, Richmond, Abdominal ultrasonography, GI, S1P, Antiemetic, Peripheral nervous system, Nursing, Pharmaceutical industry, Cryptocurrency, Electroencephalography

CHESTERBROOK, Pa., March 30, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today reported its financial results for the fourth quarter ended December 31, 2022 and provided an overview of its recent operational highlights.

Key Points: 
  • As reference, in pooled data for the Company’s pivotal Phase 3 studies of OLINVYK, the GI complete response rate was 46.2% (0.35mg) and 39.7% (0.50mg).
  • Analysis of respiratory data from VOLITION is not yet available, and the Company expects to report these data mid-2023.
  • In the fourth quarter of 2022, the commercial team signed contracts with three new specialty distributors that focus primarily on ambulatory surgery centers (ASCs).
  • Cash and cash equivalents were $38.3 million as of December 31, 2022, which the Company believes will be sufficient to fund the Company’s operating expenses and capital expenditure requirements into the fourth quarter of 2023.

Rhythmlink Announces Investment Partnership With Graham Partners

Retrieved on: 
Friday, March 17, 2023
General Health, Professional Services, Medical Devices, Hospitals, Other Manufacturing, Health Technology, Engineering, Biotechnology, Neurology, Finance, Manufacturing, Health, Epilepsy, ER, Critical care, Partnership, International, Electroencephalography, EMG, NCV, Acquisition, CFO, Growth, Entrepreneurship, ICU, Heritage365, Pharmaceutical industry, James Chalgren

Rhythmlink International, LLC is pleased to announce an exciting new investment partnership with Graham Partners, a Pennsylvania-based private equity firm that specializes in industrial technology and advanced manufacturing businesses.

Key Points: 
  • Rhythmlink International, LLC is pleased to announce an exciting new investment partnership with Graham Partners, a Pennsylvania-based private equity firm that specializes in industrial technology and advanced manufacturing businesses.
  • As a market leading designer and manufacturer of disposable neurodiagnostic devices and consumables, Rhythmlink has experienced significant growth since its founding in 2002, and this investment from Graham will ensure that growth continues along with the innovation and quality that Rhythmlink is known for.
  • “We’re excited about this next phase of Rhythmlink,” said Shawn Regan, CEO and Co-Founder.
  • Under partnership with New Heritage Rhythmlink grew rapidly, acquired Chalgren Enterprises and expanded their existing product line to include EMG and NCV diagnostic consumable devices.

Pharma Consortium Publishes Results of Large EEG/ERP Biomarker Study in Subjects with Schizophrenia and Healthy Volunteers

Retrieved on: 
Thursday, March 16, 2023
Molecule, Consortium, Drug development, Medicine, EEG, Psychiatry, Brain, Trial of the century, CSO, Cognisable offence, New York State Psychiatric Institute, Schizophrenia, Patient, Clinical Science (journal), Electroencephalography, Data analysis, DSM-IV codes, EBS, ERP, Pharmaceutical industry, Medical device, Medical imaging

LOUISVILLE, Ky., March 16, 2023 /PRNewswire/ -- The ERP Biomarker Qualification Consortium announced today the publication of all data ( https://doi.org/10.1016/j.schres.2023.02.018 ) from a large biomarker study of subjects with schizophrenia and matched healthy volunteers.

Key Points: 
  • LOUISVILLE, Ky., March 16, 2023 /PRNewswire/ -- The ERP Biomarker Qualification Consortium announced today the publication of all data ( https://doi.org/10.1016/j.schres.2023.02.018 ) from a large biomarker study of subjects with schizophrenia and matched healthy volunteers.
  • The study ( EBS-A ) was performed with 161 subjects, 80 who met the clinical criteria for schizophrenia and 81 subjects who were matched for age and gender.
  • Each study participant made three visits to one of four clinical study sites.
  • The published results include a large number of EEG/ERP parameters that equal or exceed the quality of results reported from top academic centers.

Trevena Initiates Targeted Proof-of-Concept Study to Evaluate TRV045 as a Potential Treatment for Epilepsy and Other CNS Disorders

Retrieved on: 
Tuesday, March 7, 2023
Electroencephalography, IND, Electromyography, Volunteering, Trevena, EEG, Central nervous system, PK, CNS, Disease, Male, Transcranial magnetic stimulation, EMG, Patient, Central nervous system disease, Epilepsy, TMS, S1P, Pharmaceutical industry, Medical imaging

The study will use Transcranial Magnetic Stimulation (TMS) to evaluate how TRV045 affects the ability of brain cells to conduct electrical stimulation.

Key Points: 
  • The study will use Transcranial Magnetic Stimulation (TMS) to evaluate how TRV045 affects the ability of brain cells to conduct electrical stimulation.
  • The effects of TMS will be explored using both electromyography (EMG) and electroencephalography (EEG) to measure the potential effect of TRV045 on brain function.
  • “This is the second proof-of-concept study that we have initiated to explore TRV045 as a potential treatment of epilepsy and other CNS disorders,” said Carrie Bourdow, President and CEO of Trevena.
  • “These studies are designed to build upon non-clinical data, which indicate the potential anti-inflammatory signaling and disease modifying effect of TRV045.

Global Wireless Brain Sensors Market Expected to Garner $1,566.7 Million by 2031, Growing at 9.0% CAGR from 2022 to 2031 [280-Pages] | Report by Research Dive

Retrieved on: 
Wednesday, March 1, 2023
Brain, Stroke, Traumatic brain injury, Urbanization, Migraine, Research, Hospital, MEG, Brain damage, Growth, EEG, COVID-19, Incidence, Disease, Prevalence, Medical imaging, Mobile phone, Alzheimer's disease, Electroencephalography, Epilepsy, Magnetoencephalography

NEW YORK, March 1, 2023 /PRNewswire/ -- Research Dive has added a new report to its offering titled, "Wireless Brain Sensors Market by Product Type (Electroencephalography (EEG) devices, Sleep Monitoring Devices, Magnetoencephalography (MEG) Devices, and Others), Application (Alzheimer's Disease, Traumatic Brain Injury, Epilepsy, Sleep Disorders, and Others), and End User (Hospitals, Research and Academic Institute/Laboratories, Homecare Settings, and Others): Global Opportunity Analysis and Industry Forecast, 2022-2031".

Key Points: 
  • The wireless brain sensors market is expected to grow in the 2021-2031 timeframe, due to the growing cases of traumatic brain injuries.
  • As per the report, the global wireless brain sensors market is predicted to grow at a stable CAGR of 9.0% in the 2022-2031 timeframe, thereby garnering $1,566.7 million by 2031.
  • Restraints: High cost of using wireless brain sensors, however, may dampen the growth rate of the wireless brain sensors market.
  • By regional analysis, the wireless brain sensors market in North America region is expected to flourish immensely in the forecast period.

Global Wireless Brain Sensors Market Expected to Garner $1,566.7 Million by 2031, Growing at 9.0% CAGR from 2022 to 2031 [280-Pages] | Report by Research Dive

Retrieved on: 
Wednesday, March 1, 2023
Brain, Stroke, Traumatic brain injury, Urbanization, Migraine, Research, Hospital, MEG, Brain damage, Growth, EEG, COVID-19, Incidence, Disease, Prevalence, Medical imaging, Mobile phone, Alzheimer's disease, Electroencephalography, Epilepsy, Magnetoencephalography

NEW YORK, March 1, 2023 /PRNewswire/ -- Research Dive has added a new report to its offering titled, "Wireless Brain Sensors Market by Product Type (Electroencephalography (EEG) devices, Sleep Monitoring Devices, Magnetoencephalography (MEG) Devices, and Others), Application (Alzheimer's Disease, Traumatic Brain Injury, Epilepsy, Sleep Disorders, and Others), and End User (Hospitals, Research and Academic Institute/Laboratories, Homecare Settings, and Others): Global Opportunity Analysis and Industry Forecast, 2022-2031".

Key Points: 
  • The wireless brain sensors market is expected to grow in the 2021-2031 timeframe, due to the growing cases of traumatic brain injuries.
  • As per the report, the global wireless brain sensors market is predicted to grow at a stable CAGR of 9.0% in the 2022-2031 timeframe, thereby garnering $1,566.7 million by 2031.
  • Restraints: High cost of using wireless brain sensors, however, may dampen the growth rate of the wireless brain sensors market.
  • By regional analysis, the wireless brain sensors market in North America region is expected to flourish immensely in the forecast period.

$1.63 Bn Neuromarketing Solution Markets by Technology, Electroencephalography, Eye tracking, Positron Emission Tomography and Magnetoencephalography - Global Forecasts to 2030 - ResearchAndMarkets.com

Retrieved on: 
Thursday, January 26, 2023
Marketing, Communications, Pfizer, Investment, Neuroscience, Region, Positron emission tomography, Bain Capital, Neuropsychiatry, Behavior, Growth, US, Perception, Advertising, Neuromarketing, Renewable energy, Magnetoencephalography, Electroencephalography

The "Neuromarketing Solution Market, By Technology, Electroencephalography, Eye tracking, Positron Emission Tomography and Magnetoencephalography, By Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Neuromarketing Solution Market, By Technology, Electroencephalography, Eye tracking, Positron Emission Tomography and Magnetoencephalography, By Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030" report has been added to ResearchAndMarkets.com's offering.
  • Moreover the primary objective behind neuromarketing is to understand the rationale behind how consumers make a decision for purchasing.
  • Rising investments in the field of neuroscience is the major factor driving the growth of global neuromarketing solution market.
  • Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the global Neuromarketing Solution market.